Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Feasibility of Treatment Discontinuation in Chronic Myeloid Leukemia in Clinical Practice in Spain: Results from a Nationwide Series of 236 Patients

Blood (2018) 132 (Supplement 1): 47.

https://doi.org/10.1182/blood-2018-99-109976

Published: 2018

Journal Articles

"Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial

Susanne Saussele, MD, Johan Richter, MD PhD, Joelle Guilhot, PhD, Henrik Hjorth-Hansen, MD, Antonio Medina de Almeida, MD PhD, Jeroen J. W. M. Janssen, MD, Jiri Mayer, Prof, MD SCs, Perttu Koskenvesa, MD, Panayiotis Panayiotidis, MD PhD, Ulla Olsson-Strömberg, MD PhD, Juan Luis Steegmann, MD PhD, Hanne Vestergaard, MD, Hans Ehrencrona, MD PhD, Veli Kairisto, Kateřina Machová Poláková, PhD, Martin Müller, MD, Satu Mustjoki, MDPhD, Marc G. Berger, MD PhD, Philippe Rousselot, Martine Escoffre-Barbe, MD, Gabriel Etienne, MD PhD, Jolanta Dengler, MD, Françoise Rigal-Huguet, MD, Nikolas von Bubnoff, MD, Hana Klamova, MD, Edgar Faber, MD, François Guilhot, MD, Kourosh Lotfi, MD, Delphine Rea, MD, Tim H. Brümmendorf, MD, Gorgine de Greef, MD, Leif Stenke, MD, Franck Emmanuel Nicolini, MD PhD, Laurence Legros, MD PhD, Andreas Burchert, MD, Jaroslava Voglová, MD, Aude Charbonnier, MD, Emmanuel Gyan, MDPhD, Maria-Elisabeth Goebeler, MD, Peter E. Westerweel, MD, Andreas Hochhaus, MD, Markus Pfirrmann, Francois-Xavier Mahon, MD PhD

Blood (2017) 130 (Supplement 1): 313.

https://doi.org/10.1182/blood.V130.Suppl_1.313.313

Published: 2017

Journal Articles

A Conservative Tailoring of Ponatinib Dose in Chronic Myeloid Leukemia Patients Can Diminish Adverse Events While Maintaining Efficacy

Blood (2017) 130 (Supplement 1): 1624.

https://doi.org/10.1182/blood.V130.Suppl_1.1624.1624

Published: 2017

Journal Articles

Real Life Long-Term Survival Analysis in Patients with Chronic Myeloid Leukemia Treated with Tkis in Spain

Luis Felipe Casado Montero, Valentin Garcia Gutierrez, MD, Pilar Giraldo, MD PhD, Manuel Perez-Encinas, Raquel de Paz, Joaquin Martinez-Lopez, Guiomar Bautista, Santiago Osorio, Maria Jose Requena, Luis Palomera, MD PhD, Maria Jesús Peñarrubia, Carmen Calle, Jose Angel Hernandez-Rivas, Nuria García-Ormeña, Juan Luis Steegmann, MD PhD

Blood (2016) 128 (22): 3074.

https://doi.org/10.1182/blood.V128.22.3074.3074

Published: 2016

Journal Articles

Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy

Blood (2016) 128 (22): 625.

https://doi.org/10.1182/blood.V128.22.625.625

Published: 2016

Journal Articles

Measurement of PTCH1 Expression at Diagnosis Is an Appropriate Tool for Tyrosine Kinase Inhibitors Selection in Chronic Myeloid Leukemia Patients in Chronic Phase

Juan Manuel Alonso-Dominguez, MD, Felipe Casado, MariaTeresa Gómez Casares, MDPhD, Ismael Buno, Francisca Ferrer-Marin, Eduardo Anguita, MD PhD, Alicia Arenas, Rafael Del Orbe, MD, Rosa M. Ayala, MD PhD, Pilar Llamas, MD, Pedro Sanchez-Godoy, MD, Carmen Burgaleta, MD, Valentín García-Gutierrez, Juan Luis Steegmann, MD PhD, Joaquin Martinez-Lopez

Blood (2015) 126 (23): 2791.

https://doi.org/10.1182/blood.V126.23.2791.2791

Published: 2015

Journal Articles

Incidence of CML in Europe—a Comparison of 19 European Countries with US SEER Data

Blood (2014) 124 (21): 3145.

https://doi.org/10.1182/blood.V124.21.3145.3145

Published: 2014

Journal Articles

Baseline Characteristics of CML Patients Accross Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials

Blood (2014) 124 (21): 3160.

https://doi.org/10.1182/blood.V124.21.3160.3160

Published: 2014

Journal Articles

Bosutinib Apears to be Safe, with Low Cross Intolerance, in Patients Treated in 4th Line. Results of the Spanish Compassionate Use Program

Blood (2014) 124 (21): 5523.

https://doi.org/10.1182/blood.V124.21.5523.5523

Published: 2014

Journal Articles

CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry

Verena S Hoffmann, PhD, Doris Lindoerfer, Dipl.-Inf., Markus Pfirrmann, PhD, Susanne Saussele, MD, Andreas Hochhaus, MD, Jutta Engel, PhD, MD, Joelle Guilhot, PhD, Gianantonio Rosti, Jiri Mayer, MD, PhD, Karel Indrak, MD, Fausto Castagnetti, Anna Turkina, Andrey Zaritskey, MD, PhD, Juan Luis Steegmann, MD, PhD, Andrzej Hellmann, Noortje Thielen, MD, Francisco Cervantes, MD, PhD, Bengt Simonsson, MD, PhD, Adriana Colita, MD, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Antonio Almeida, MD, PhD, Boris Labar, MD, PhD, David Marin, MD, Gert J. Ossenkoppele, MD PhD, Andrija Bogdanovic, Irina Dyagil, Kimmo Porkka, MD, PhD, Stephen O'Brien, Laimonas Griskevicius, Panagiotis Panagiotidis, MD, Josef Thaler, MD, Irena Zupan, MD, PhD, Sandra Lejniece, PhD, MD, Hele Everaus, MD, PhD, Tamás Masszi, MD, PhD, Frederiki Melanthiou, Rüdiger Hehlmann, Joerg Hasford, MD, Michele Baccarani, MD

Blood (2013) 122 (21): 2735.

https://doi.org/10.1182/blood.V122.21.2735.2735

Published: 2013

Journal Articles

Deep Molecular Responses In Patients With Newly Diagnosed Chronic Myeloid Leukemia Receiving Nilotinib As Assessed Within The EUTOS Laboratory Network In The ENEST1st Study

Blood (2013) 122 (21): 4030.

https://doi.org/10.1182/blood.V122.21.4030.4030

Published: 2013

Journal Articles

Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data

Giuseppe Saglio, MD, Hagop M. Kantarjian, MD, Neil Shah, MD, PhD, Elias J. Jabbour, MD, Alfonso Quintas-Cardama, MD, Juan Luis Steegmann, MD, PhD, Concepción Boqué, MD, Charles Chuah, MD, Carolina Pavlovsky, MD, Jiří Mayer, MD, Jon Ukropec, PhD, Mark Wildgust, PhD, Andreas Hochhaus, MD

Blood (2012) 120 (21): 1675.

https://doi.org/10.1182/blood.V120.21.1675.1675

Published: 2012

Journal Articles

Outcomes of Chronic Myeloid Leukemia (CML) Patients Who Stopped Second Generation Tyrosine Kinase Inhibitors (2GTKIs) As Second Line Treatment. Results of the CML Spanish National Registry (RELMC)

J Valentin Garcia-Gutierrez, MD, PhD, Begoña Maestro, Luis Felipe Casado, MD, PhD, Manuel Perez-Encinas, Isabel Massague, Raquel de Paz, Santiago Osorio, Joaquin Martinez, MD, Guiomar Bautista, MD, Pilar Giraldo, Carmen Burgaleta, Maria Jesús Peñarrubia, Maria José Requena, Carmen Calle, Jose Ángel Hernández-Rivas, Pilar Cano, Juan Luis Steegmann, MD, PhD

Blood (2012) 120 (21): 3764.

https://doi.org/10.1182/blood.V120.21.3764.3764

Published: 2012

Journal Articles

Switching to a Second Generation TKI in Chronic Myeloid Leukemia Patients with Late Suboptimal Response with Imatinib Obtained Better Molecular Responses That the “Watch and Wait” Approach. an Experience of a Multicenter Registry in Patients Outside Clinical Trials

J Valentin Garcia-Gutierrez, MD, PhD, Begoña Maestro, Luis Felipe Casado, MD, PhD, Manuel Perez-Encinas, Isabel Massague, Raquel De Paz, MD, Santiago Osorio, Joaquin Martinez, MD, Guiomar Bautista, MD, Pilar Giraldo, Carmen Burgaleta, Maria Jesús Peñarrubia, Maria José Requena, Carmen Calle, Jose Angel Hernandez-rivas, MD, Pilar Cano, Juan Luis Steegmann, MD, PhD

Blood (2012) 120 (21): 3768.

https://doi.org/10.1182/blood.V120.21.3768.3768

Published: 2012

Journal Articles

A Good Adherence to ELN 09 Recommendations in Chronic Myeloid Leukemia (CML) Treatment with Imatinib, Is Associated with Better Outcomes in Patients Treated Outside Clinical Trials

Blood (2012) 120 (21): 3762.

https://doi.org/10.1182/blood.V120.21.3762.3762

Published: 2012

Journal Articles

Outcome of Patients with Chronic Myeloid Leukemia After Allogeneic Stem Cell Transplantation in Europe; Data From the EUTOS for CML Registry

Blood (2011) 118 (21): 1688.

https://doi.org/10.1182/blood.V118.21.1688.1688

Published: 2011

Journal Articles

Effect of Time to Dasatinib Initiation On Outcome of Imatinib-Intolerant Patients with Chronic-Phase Chronic Myelogenous Leukemia (CP-CML): Results From a European Observational Study (FORTE; CA180–211)

David Marin, Enrica Morra, MD, Mauricette Michallet, Andrzej Hellmann, MD, Dietger Niederwieser, MD, Ernst Schloegl, MD, Mats Björeman, MD, Kajetana Foryciarz, MD, PhD, Aloysius Y Ho, Kazimierz Kuliczkowski, Gert Ossenkoppele, MD, PhD, Antonella Gozzini, MD, M. Lurdes Guerra, MD, Gregor Verhoef, Ave Mori, MD, Miranda Pans, Marc van Baardewijk, Pharm.D, Juan Luis Steegmann, MD, PhD

Blood (2011) 118 (21): 1689.

https://doi.org/10.1182/blood.V118.21.1689.1689

Published: 2011

Journal Articles

Survival and Response Outcomes to Different Treatment Schedules in CML Patients Starting Therapy with Imatinib. Results from the CML Spanish Registry (RELMC)

Luis Felipe Casado, Isabel Massague, Pilar Giraldo, PhD, Manuel Perez-Encinas, Raquel De Paz, MD, Joaquín Martínez-López, Guiomar Bautista, Santiago Osorio, Maria José Requena, Luis Palomera, Maria Jesús Peñarrubia, Carmen Calle, Begoña Maestro, Juan Luis Steegmann, MD, PhD

Blood (2010) 116 (21): 1237.

https://doi.org/10.1182/blood.V116.21.1237.1237

Published: 2010

Journal Articles

Hypophosphatemia During Imatinib Treatment of Newly Diagnosed Chronic Myeloid Leukemia Patients Is Associated with Better Response.

Luis Felipe Casado, MD, PhD, Isabel Massague, MD, Pilar Giraldo, MD, Manuel Pérez-Encinas, MD, Raquel de Paz, MD, PhD, Joaquin Martínez-López, MD, PhD, Rafael Fores, MD, Santiago Osorio, MD, Maria José Requena, MD, Luis Palomera, MD, María Jesus Peñarrubia, MD, Carmen Burgaleta, MD, PhD, Begoña Maestro, PhD, Juan Luis Steegmann, MD, PhD

Blood (2009) 114 (22): 1121.

https://doi.org/10.1182/blood.V114.22.1121.1121

Published: 2009

Journal Articles

Transforming and Tumorogenic Activity of JAK2 by Fusion to BCR: Molecular Mechanisms of Action of a Novel BCR-JAK2 Tyrosin-Kinase.

Álvaro Cuesta-Domínguez, Mara Ortega, Cristina Ormazabal, Matilde Santos-Roncero, Marta Galán-Díez, Juan Luis Steegmann, MD, PhD, Eva Arranz, María Ángeles Figuera, Jaqueline Sayyah, MS, Peter P. Sayeski, PhD, José Luis Vizmanos, Juan A. Bueren, Paula Rio, Elena Fernandez-Ruiz

Blood (2009) 114 (22): 4683.

https://doi.org/10.1182/blood.V114.22.4683.4683

Published: 2009

NARROW

Feasibility of Treatment Discontinuation in Chronic Myeloid Leukemia in Clinical Practice in Spain: Results from a Nationwide Series of 236 Patients

"Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial

A Conservative Tailoring of Ponatinib Dose in Chronic Myeloid Leukemia Patients Can Diminish Adverse Events While Maintaining Efficacy

Real Life Long-Term Survival Analysis in Patients with Chronic Myeloid Leukemia Treated with Tkis in Spain

Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy

Measurement of PTCH1 Expression at Diagnosis Is an Appropriate Tool for Tyrosine Kinase Inhibitors Selection in Chronic Myeloid Leukemia Patients in Chronic Phase

Incidence of CML in Europe—a Comparison of 19 European Countries with US SEER Data

Baseline Characteristics of CML Patients Accross Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials

Bosutinib Apears to be Safe, with Low Cross Intolerance, in Patients Treated in 4th Line. Results of the Spanish Compassionate Use Program

CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry

Deep Molecular Responses In Patients With Newly Diagnosed Chronic Myeloid Leukemia Receiving Nilotinib As Assessed Within The EUTOS Laboratory Network In The ENEST1st Study

Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data

Outcomes of Chronic Myeloid Leukemia (CML) Patients Who Stopped Second Generation Tyrosine Kinase Inhibitors (2GTKIs) As Second Line Treatment. Results of the CML Spanish National Registry (RELMC)

Switching to a Second Generation TKI in Chronic Myeloid Leukemia Patients with Late Suboptimal Response with Imatinib Obtained Better Molecular Responses That the “Watch and Wait” Approach. an Experience of a Multicenter Registry in Patients Outside Clinical Trials

A Good Adherence to ELN 09 Recommendations in Chronic Myeloid Leukemia (CML) Treatment with Imatinib, Is Associated with Better Outcomes in Patients Treated Outside Clinical Trials

Outcome of Patients with Chronic Myeloid Leukemia After Allogeneic Stem Cell Transplantation in Europe; Data From the EUTOS for CML Registry

Effect of Time to Dasatinib Initiation On Outcome of Imatinib-Intolerant Patients with Chronic-Phase Chronic Myelogenous Leukemia (CP-CML): Results From a European Observational Study (FORTE; CA180–211)

Survival and Response Outcomes to Different Treatment Schedules in CML Patients Starting Therapy with Imatinib. Results from the CML Spanish Registry (RELMC)

Hypophosphatemia During Imatinib Treatment of Newly Diagnosed Chronic Myeloid Leukemia Patients Is Associated with Better Response.

Transforming and Tumorogenic Activity of JAK2 by Fusion to BCR: Molecular Mechanisms of Action of a Novel BCR-JAK2 Tyrosin-Kinase.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only